Research & Development
Over 21% of global net sales are reinvested in research and development
DAIICHI SANKYO as it is today was established in September 2005, following the merger of two major Japan-based pharmaceutical companies, SANKYO Co Ltd and DAIICHI Pharmaceutical Co Ltd. Both companies had consistently delivered industry breakthroughs over more than 100 years.
Among their milestones are being the first company to isolate adrenaline, in 1900, and the first to identify vitamin B1, in 1910. Then followed the first cephamycin antibiotic in Japan in 1951, and the discovery of statins in 1971 – which revolutionised the lowering of high cholesterol. They pioneered the treatment of type 2 diabetes, with the first glitazone – in the 1990s – as well as significant advances in antibiotic therapy and treatments for hypertension, angina and heart failure.
This innovative spirit is at the core of present day DAIICHI SANKYO. By 2015 we aim to reach a net sales of 1.5 trillion yen, equivalent to £7.5 billion.
Among their milestones are being the first company to isolate adrenaline, in 1900, and the first to identify vitamin B1, in 1910. Then followed the first cephamycin antibiotic in Japan in 1951, and the discovery of statins in 1971 – which revolutionised the lowering of high cholesterol. They pioneered the treatment of type 2 diabetes, with the first glitazone – in the 1990s – as well as significant advances in antibiotic therapy and treatments for hypertension, angina and heart failure.
This innovative spirit is at the core of present day DAIICHI SANKYO. By 2015 we aim to reach a net sales of 1.5 trillion yen, equivalent to £7.5 billion.
